Life Science Angels

Trio Pharmaceuticals is a San Diego-based company focused on developing innovative cancer therapeutics. Founded in 2018, it specializes in dual-action drugs designed to combat immunogenic tumors. These therapeutics aim to halt tumor growth while selectively addressing immunosuppression within the tumor environment, distinct from conventional immune checkpoint pathways. By targeting specific antigens on cancer cells and immunosuppressor cells, Trio's drugs enhance tumor immunity, improve treatment efficacy, and reduce toxicity. The company's mission is to address significant unmet medical needs in cancer treatment, ultimately making therapies more accessible and affordable for patients.

Pelvital USA, Inc. is a privately held company based in Minneapolis, Minnesota, focused on restoring pelvic health and enhancing the quality of life for individuals suffering from pelvic floor disorders. Founded in 2016, the company is currently evaluating the Flyte system, an investigational medical device designed to strengthen and potentially heal the pelvic floor muscle system. This device employs a unique mechanotherapy technology, which has been shown to effectively heal and strengthen muscle systems. Through its innovative approach, Pelvital aims to provide significant improvements for patients dealing with pelvic floor issues.

Neurava is a company focused on developing non-invasive wearable diagnostic devices for patients with epilepsy, particularly those at risk of Sudden Unexpected Death in Epilepsy (SUDEP). The company's innovative device monitors critical biological signals related to epilepsy, providing timely alerts to caregivers and patients. By offering a reliable monitoring solution, Neurava aims to enhance patient autonomy and deliver peace of mind to families, facilitating timely intervention when necessary. The company's work lies at the intersection of medical device manufacturing and health diagnostics, addressing a significant need within the epilepsy patient community.

Averto Medical is a manufacturer of medical devices focused on addressing gastrointestinal diseases. The company specializes in developing innovative solutions designed to facilitate minimally invasive colorectal tumor removal, which aims to reduce the need for multiple surgical procedures and associated complications. By providing effective medical care options for patients suffering from gastrointestinal disorders, Averto Medical seeks to improve patient outcomes and streamline treatment processes in this critical area of healthcare.

Astrocyte Pharmaceuticals Inc. is a drug development company focused on creating neuroprotection therapies for conditions such as traumatic brain injuries (TBI), concussions, acute ischemic stroke, and neurodegenerative disorders like Alzheimer's disease. Founded in 2014 and located in Cambridge, Massachusetts, the company is dedicated to demonstrating the neuroprotective benefits of selectively activating astrocytes. Its lead product, AST-004, is a novel small molecule designed for acute administration, aiming to protect and repair damaged neurons. Through its innovative approaches, Astrocyte Pharmaceuticals seeks to improve the recovery and well-being of patients suffering from brain injuries.

Avisi Technologies Inc. is a company based in Philadelphia, Pennsylvania, that focuses on developing innovative solutions for glaucoma treatment. Founded in 2017, the company has created VisiPlate, a next-generation aqueous shunt that utilizes nanotechnology to provide a defense against blindness caused by glaucoma. This advanced technology aims to improve the effectiveness of glaucoma treatments and enhance patient outcomes.

InnoSIGN specializes in mRNA-based pathway activity profiling technology, aimed at advancing precision medicine by offering deeper insights into disease mechanisms. The company leverages a comprehensive library of pathway activity profiles to enhance diagnostics and facilitate drug discovery. It provides researchers with quantitative PCR (qPCR) tests designed for decentralized use, which are available through a service testing facility located in the Netherlands. Through its innovative approach, InnoSIGN seeks to transform the understanding and treatment of various diseases.

Allyx Therapeutics, founded in 2018 and based in Durham, Connecticut, is a clinical-stage biotechnology company focused on developing disease-modifying treatments for Alzheimer's Disease. The company’s primary product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative drug aims to reverse neurodegeneration and offers a potential approach to preserve cognitive function in patients with Alzheimer's. By targeting the underlying mechanisms of the disease, Allyx Therapeutics strives to provide effective therapeutic solutions for those affected by neurodegenerative disorders.

Astrocyte Pharmaceuticals Inc. is a drug development company focused on creating neuroprotection therapies for conditions such as traumatic brain injuries (TBI), concussions, acute ischemic stroke, and neurodegenerative disorders like Alzheimer's disease. Founded in 2014 and located in Cambridge, Massachusetts, the company is dedicated to demonstrating the neuroprotective benefits of selectively activating astrocytes. Its lead product, AST-004, is a novel small molecule designed for acute administration, aiming to protect and repair damaged neurons. Through its innovative approaches, Astrocyte Pharmaceuticals seeks to improve the recovery and well-being of patients suffering from brain injuries.

Strategikon Pharma, Inc. specializes in developing software that optimizes the outsourcing processes between sponsors and providers in the pharmaceutical industry. Its flagship product, Clinical Maestro, is a unique platform designed for the comprehensive management of clinical business operations, particularly in planning, outsourcing, and budgeting clinical trials. By facilitating an integrated virtual environment, Clinical Maestro enables biopharmaceutical companies to efficiently manage complex relationships with numerous global service providers who often operate with varying processes and reporting structures. The software replaces traditional, labor-intensive methods—primarily reliant on Excel—leading to significant cost savings and enhanced operational efficiency. Case studies with major pharmaceutical firms highlight the platform's effectiveness, achieving over 80% savings compared to manual processes and over 95% accuracy in predicting clinical study budgets. Founded in 2016 and headquartered in San Rafael, California, Strategikon Pharma also offers consulting services to support new clinical business operations.

Visicell Medical is a company focused on developing innovative medical imaging technology that enhances the early detection and diagnosis of diseases. It specializes in creating safe and biodegradable stem cell tracking tools, which facilitate real-time monitoring of stem cells implanted in patients. These tools are designed for use in both clinical and pre-clinical settings, allowing healthcare professionals to track stem cell progress effectively. In addition to stem cell tracking, Visicell Medical offers specialized image capture systems and analysis tools that provide high-resolution, three-dimensional views of tissues and cells. This technology aids in the identification of abnormalities, enabling earlier intervention and improved treatment outcomes for patients, while also aiming to reduce overall healthcare costs.

Avisi Technologies Inc. is a company based in Philadelphia, Pennsylvania, that focuses on developing innovative solutions for glaucoma treatment. Founded in 2017, the company has created VisiPlate, a next-generation aqueous shunt that utilizes nanotechnology to provide a defense against blindness caused by glaucoma. This advanced technology aims to improve the effectiveness of glaucoma treatments and enhance patient outcomes.

Celldom, Inc. is a research tools company based in Durham, North Carolina, established in 2016. It specializes in single-cell analysis technology aimed at enhancing research, drug discovery, and development by revealing the diversity within cell populations. The company's flagship product, the TrapTx Analyzer System, integrates phenotypic and genomic data on a large scale, allowing for the identification and characterization of rare cells that are crucial in various biological pathways and diseases. Celldom focuses on applications in oncology, immunology, and stem cell biology, providing innovative solutions that enable researchers to automate the analysis of cellular heterogeneity effectively.

Saccharo is a biotech start-up focused on developing innovative therapeutic products for cancer treatment and other emerging diseases. Established in 2017 by Sherry Martin-Moe and Gregory Moe in Oakland, California, the company has identified a unique polysaccharide that encases human cancer cells. This discovery facilitates a novel approach to immuno-oncology, allowing for therapies that employ a mechanism of action with multiple killing effects. Saccharo's treatments are designed to offer a favorable safety profile and a broad therapeutic window, making them applicable to various types of cancers. Through its research and development efforts, Saccharo aims to enhance the effectiveness of cancer therapies and improve patient outcomes.

Allyx Therapeutics, founded in 2018 and based in Durham, Connecticut, is a clinical-stage biotechnology company focused on developing disease-modifying treatments for Alzheimer's Disease. The company’s primary product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative drug aims to reverse neurodegeneration and offers a potential approach to preserve cognitive function in patients with Alzheimer's. By targeting the underlying mechanisms of the disease, Allyx Therapeutics strives to provide effective therapeutic solutions for those affected by neurodegenerative disorders.

Strategikon Pharma, Inc. specializes in developing software that optimizes the outsourcing processes between sponsors and providers in the pharmaceutical industry. Its flagship product, Clinical Maestro, is a unique platform designed for the comprehensive management of clinical business operations, particularly in planning, outsourcing, and budgeting clinical trials. By facilitating an integrated virtual environment, Clinical Maestro enables biopharmaceutical companies to efficiently manage complex relationships with numerous global service providers who often operate with varying processes and reporting structures. The software replaces traditional, labor-intensive methods—primarily reliant on Excel—leading to significant cost savings and enhanced operational efficiency. Case studies with major pharmaceutical firms highlight the platform's effectiveness, achieving over 80% savings compared to manual processes and over 95% accuracy in predicting clinical study budgets. Founded in 2016 and headquartered in San Rafael, California, Strategikon Pharma also offers consulting services to support new clinical business operations.

Anubis Bio Corporation is a medical nutrition company based in Orlando, Florida, that focuses on developing and manufacturing products aimed at controlling diarrhea in dogs and cats. Incorporated in 2018, the company offers DoggyStat, a product designed to provide symptomatic relief and eliminate infections that cause diarrhea in pets. Anubis Bio utilizes a patented Microbiome-Cleanser natural food platform that addresses gastrointestinal distress in animals, beginning with dogs. The company's approach emphasizes enhancing pet health through natural food products that support digestive health and normal intestinal function. In 2021, Anubis Bio established two significant B2B distribution partnerships to expand its reach in the animal health management sector.

Noctrix Health, Inc. is an early-stage medical device company based in Menlo Park, California, founded in 2018. The company specializes in developing therapeutic wearable devices aimed at treating chronic neurological and sleep disorders, particularly focusing on restless leg syndrome. Its innovative device utilizes neural circuitry to alleviate symptoms and promote undisturbed sleep, empowering patients to better manage their chronic medical conditions.

iDENTICAL, Inc. specializes in creating personalized dental implants tailored to the unique structure of each patient’s tooth. Founded in 2018 and headquartered in Mountain View, California, the company focuses on making tooth replacement more accessible and affordable through its innovative drill-free, non-invasive implants. Utilizing advanced 3D scanning and printing technology, iDENTICAL enables dentists to provide customized dental implants efficiently and safely. This approach revolutionizes the traditional tooth replacement process, allowing family dentists to offer a streamlined treatment option for individuals experiencing tooth loss.

BioTrace Medical, Inc. is a medical device company based in California, focused on developing a temporary cardiac pacing device aimed at treating reversible symptomatic bradycardia. Founded in 2013 by Aravind Swaminathan and Ellis Garai, the company seeks to enhance patient outcomes and lower hospital costs through its innovative technology. The device is designed to provide secure and stable pacing, thereby minimizing complications and facilitating earlier patient ambulation following cardiac procedures. Through its advancements, BioTrace Medical aims to improve the quality of care for patients undergoing cardiac surgery.

Stimwave LLC is a medical device company focused on developing, manufacturing, and marketing wireless microsize injectable devices for neurology applications. The company's product offerings include the Freedom SCS System, a spinal cord stimulator designed to alleviate chronic low back and leg pain, and the StimQ PNS System, a peripheral nerve stimulator that addresses chronic pain by targeting specific peripheral nerves. Originally incorporated as Neural Micro Incorporated in 2010, Stimwave LLC is headquartered in Pompano Beach, Florida.

Eumentis Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapeutics for neurodevelopmental and neurodegenerative diseases. Founded in 2019 and based in Newton, Massachusetts, the company is advancing several product candidates, including EM-036, a nitroaminoadamantane NMDA receptor antagonist aimed at treating Alzheimer's disease and autism-spectrum disorders. Additionally, Eumentis is developing EM-221, an oral PDE10A inhibitor that targets the dopamine D2 pathway in the striatum to address neuropsychiatric conditions. The company also offers pre-clinical study, development, and testing services, leveraging insights into brain function to enhance treatment options in the healthcare sector.

Sandstone Diagnostics, Inc. is a technology and healthcare company based in Pleasanton, California, founded in 2012. The company specializes in developing medical products and research tools focused on male fertility management. Its notable offerings include the Torq ZDrive, which separates blood cells from liquid plasma at the point of collection, and the Torq Microvolume Rotor, a remote blood sampling device for diagnostic testing. Sandstone also manufactures the Trak fertility system, which consists of an engine, a disposable test plate, a sample collection cup, and a dropper, allowing men to monitor their sperm quality and enhance their fertility potential. Additionally, the company provides a mobile application that allows users to track fertility statistics over time, identify potential fertility issues, and take proactive steps to improve their reproductive health. Through these innovations, Sandstone Diagnostics aims to empower individuals to manage their fertility from the comfort of their own homes.

S2 Genomics, Inc. is a company based in Livermore, California, that specializes in developing advanced spatial sequencing technology. Founded in 2016, the company focuses on creating integrated sample preparation systems that automate the processing of solid tissues and liquid samples into genomic samples. This technology allows researchers to isolate single cells or nuclei from raw tissues, facilitating genomics and cell biology studies. S2 Genomics aims to streamline the preparation process, ensuring reproducibility and minimal impact on cellular transcriptomes, thereby optimizing the quantity and quality of viable cells or nuclei derived from various tissue types.

Inhalon Biopharma, Inc. is focused on developing monoclonal antibodies that utilize innovative technology to trap pathogens in mucus secretions, specifically targeting respiratory infections. Founded in 2018 and based in Carrboro, North Carolina, the company aims to provide treatments and preventative solutions for respiratory syncytial virus (RSV), a significant cause of lung and respiratory tract infections in children. Inhalon Biopharma's inhaled immunotherapy platform is designed to harness the power of biologics for mucosal applications, enabling healthcare providers to effectively address acute respiratory infections.

S2 Genomics, Inc. is a company based in Livermore, California, that specializes in developing advanced spatial sequencing technology. Founded in 2016, the company focuses on creating integrated sample preparation systems that automate the processing of solid tissues and liquid samples into genomic samples. This technology allows researchers to isolate single cells or nuclei from raw tissues, facilitating genomics and cell biology studies. S2 Genomics aims to streamline the preparation process, ensuring reproducibility and minimal impact on cellular transcriptomes, thereby optimizing the quantity and quality of viable cells or nuclei derived from various tissue types.

VALFIX Medical Ltd designs and develops transcatheter solution that combines repair and replacement for Mitral or Tricuspid valve. The company was founded in 2016 and is headquartered in Tel Aviv, Israel.

Embolx, Inc. is a medical device company based in Sunnyvale, California, specializing in catheter-based systems for cancer therapy. Founded in 2013, the company develops innovative devices that enhance minimally invasive treatments, particularly through a technology known as Low Pressure Embolization (LPE). Their flagship product, the Sniper drug delivery balloon microcatheter, allows for precise tracking and controlled drug delivery, significantly improving tumor treatment while minimizing non-target flow and protecting surrounding tissues. Embolx's advanced microcatheters are designed not only for cancerous tumors but also for conditions such as benign prostatic hyperplasia and uterine fibroids, setting a new standard in embolic delivery and targeting effectiveness.

Chimera Bioengineering focuses on developing gene therapeutics that aim to reprogram the immune system for cancer treatment. Their innovative approach utilizes chimeric antigen receptor T-cells (CARs), which are engineered immune cells designed to overcome immune evasion by targeting and eliminating tumor cells that express specific antigens. While existing CAR therapies have shown promise in treating liquid tumors such as acute lymphoblastic leukemia and lymphoma, challenges remain in addressing solid tumors, managing toxicities, and ensuring long-lasting effectiveness. Chimera Bioengineering addresses these limitations by incorporating drug-responsive gene regulators that enhance CAR functionality. This strategy aims to minimize adverse effects, improve therapeutic efficacy, and extend the persistence of CARs, ultimately striving for more effective and sustainable cures for cancer patients, particularly those who have not responded to traditional therapies.

Chameleon Biosciences Inc. specializes in developing gene therapy solutions using Adeno Associated Virus (AAV) technology to address rare genetic diseases. Founded in 2017 and based in San Anselmo, California, the company focuses on delivering therapeutic proteins to targeted tissues while minimizing immune responses to enhance gene delivery and reduce immunogenicity. Chameleon aims to transform the treatment landscape for genetic disorders, particularly in infants, where a significant percentage of fatalities are attributed to these conditions. The company is dedicated to ensuring that affected children receive accurate, lower-dose treatments that can be administered multiple times as needed. By masking foreign proteins and shielding the viral capsid from antibodies, Chameleon seeks to increase the range of diseases that can be treated effectively, thereby improving patient outcomes and quality of life.

TeVido BioDevices, Inc. is a biotechnology start-up based in Austin, Texas, focused on developing innovative tissue-engineered products for reconstructive surgery. Founded in 2016, the company utilizes a platform technology that combines 3D bio-printing with a patient's living cells to create custom grafts. These grafts specifically address the needs of individuals who have lost skin color due to scarring or disease, offering improved options for reconstruction. TeVido's technology not only aims to restore lost pigment but also has potential applications in wound healing and cosmetic surgery, ultimately enhancing patient outcomes and quality of life.

First Light Diagnostics Inc. specializes in the development of automated medical diagnostic products aimed at detecting microbes responsible for healthcare-associated infections. The company is known for its benchtop MultiPath analyzer, which identifies both resistant and sensitive strains of Staphylococcus aureus, as well as various toxins and viruses, making it suitable for hospital clinical microbiology laboratories. Its products address multiple applications, including the screening of blood, surgical, skin, and gastrointestinal infections. By offering rapid and cost-effective testing solutions, First Light Diagnostics meets the increasing demand for accurate diagnostics, which is essential for reducing hospital infection rates. The company's proprietary MultiPath detection technology combines the efficiency of advanced laboratory tests with affordability and ease of use. Founded in 2006 and based in Chelmsford, Massachusetts, First Light Diagnostics was previously known as First Light Biosciences until its name change in January 2019.

S2 Genomics, Inc. is a company based in Livermore, California, that specializes in developing advanced spatial sequencing technology. Founded in 2016, the company focuses on creating integrated sample preparation systems that automate the processing of solid tissues and liquid samples into genomic samples. This technology allows researchers to isolate single cells or nuclei from raw tissues, facilitating genomics and cell biology studies. S2 Genomics aims to streamline the preparation process, ensuring reproducibility and minimal impact on cellular transcriptomes, thereby optimizing the quantity and quality of viable cells or nuclei derived from various tissue types.

TransformativeMed, Inc. develops software solutions aimed at enhancing hospital operations and improving patient care. Founded in 2007 and headquartered in Seattle, the company provides a platform that integrates with electronic medical records (EMR) and clinician workflows, allowing healthcare professionals to access vital patient data seamlessly across various clinical specialties and departments. Its key offerings include Smart Health Apps, which utilize the MPages development toolkit for enhanced user interfaces, and specific solutions such as CORES Smart Handoffs, a streamlined sign-out process for providers; GlycemiCare Smart Glucose, which aids in managing glycemic control for inpatient teams; and ACR Select Smart Imaging, which incorporates imaging decision support directly into the EMR at the point of order entry. By automating data recording and facilitating better communication among healthcare providers, TransformativeMed aims to focus on improving patient outcomes.

Purissima, Inc. is a biotherapeutics company founded in 2017 and headquartered in Sunnyvale, California. The company specializes in producing active pharmaceutical ingredient (API) grade molecules by leveraging a unique platform that utilizes the fermentation of heterotrophic microalgae. Through this innovative approach, Purissima aims to advance the development of biotherapeutics and contribute to the pharmaceutical industry.

Virion Therapeutics, LLC is a biotechnology company focused on developing immune-based treatments for virally associated cancers and chronic viral infections. Founded in 2018 and headquartered in Newark, Delaware, the company offers innovative vaccines, ChiVax and ChiVax-gD, which aim to induce potent and sustained T cell-mediated immune responses against transformed or infected cells. These chimeric vaccine candidates have successfully completed pre-clinical testing, paving the way for clinical trials targeting diseases with significant unmet medical needs, such as HPV-induced cancers and chronic Hepatitis B infections. Virion Therapeutics combines scientific expertise with management experience to advance its immunotherapy platforms, which may ultimately improve patient outcomes in the fight against these challenging health issues.

Ark.one Health specializes in developing a predictive analytics platform tailored for health care systems and plans. The platform employs proprietary algorithms to identify opportunities for cost savings and to provide ongoing monitoring of financial performance improvements. By offering these analytics as a service, Ark.one Health enables CFOs and healthcare managers to enhance the financial efficiency of their operations and improve the management of value-based contracts.

Seal Rock Therapeutics is a biotechnology company focused on developing small-molecule inhibitors targeting ASK1 (Apoptosis signal-regulating kinase 1), a protein involved in apoptosis, inflammation, and fibrosis. The company primarily aims to address hepatic conditions, particularly non-alcoholic steatohepatitis (NASH), which is a fatty liver disease characterized by inflammation and cellular damage leading to liver fibrosis. In addition to NASH, Seal Rock is exploring the potential of ASK1 inhibitors for treating various other conditions, including cardiac, immunological, and neurodegenerative diseases, which currently lack effective therapies.

TheraDep specializes in the development of surface coatings for microneedles and labware, targeting the medical device and pharmaceutical sectors. The company creates biocompatible coatings that are drug-eluting, growth-promoting, and therapeutic, utilizing a patented process to meet the specific requirements of its clients. By collaborating with medical device and labware manufacturers, TheraDep aims to deliver innovative drug delivery solutions that enhance patient treatment outcomes.

InvVax, Inc. is a vaccine development company based in Los Angeles, California, founded in 2012. The company focuses on creating innovative vaccines, with its primary product being a universal influenza vaccine aimed at preventing pandemics. Utilizing a proprietary platform, InvVax's technology analyzes influenza proteins to address virus mutations, thereby enhancing the effectiveness of vaccines. In addition to its work on influenza, InvVax is exploring vaccine candidates for other viral infections, including HIV, Hepatitis B, and Hepatitis C.

Mission Bio, Inc. is a biotechnology company that specializes in tools for studying cellular heterogeneity in human health and life sciences. The company has developed the Tapestri Platform, the first single-cell multi-omics platform, which allows for the simultaneous analysis of genotype and phenotype from the same cell. This platform utilizes proprietary microfluidic droplet technology to enable precise detection of genomic variability at single-cell resolution, facilitating research in various applications, including oncology, blood cancers, solid tumors, and genome editing. Additionally, Mission Bio offers Tapestri Designer, a cloud-based tool for creating customized single-cell DNA panels, further enhancing its capabilities in targeted molecular analysis. Founded in 2011 and based in South San Francisco, California, the company was previously known as Torrent Bio, Inc. before rebranding in 2013.

Nanotech Biomachines specializes in the development of advanced sensor technology aimed at transforming therapeutic discovery and development processes. By utilizing modern electronic materials and straightforward membrane preparations, the company achieves high sensitivity and specificity in its measurements. Its innovative approach employs naive biology to enable real-time, mass-independent, cell-free, and label-free detection of interactions with integral membrane proteins (IMPs). This technology offers a direct electronic output and utilizes native IMPs within fluid membranes, providing essential tools for clients engaged in the discovery and development of 21st-century medicines.

Seal Rock Therapeutics is a biotechnology company focused on developing small-molecule inhibitors targeting ASK1 (Apoptosis signal-regulating kinase 1), a protein involved in apoptosis, inflammation, and fibrosis. The company primarily aims to address hepatic conditions, particularly non-alcoholic steatohepatitis (NASH), which is a fatty liver disease characterized by inflammation and cellular damage leading to liver fibrosis. In addition to NASH, Seal Rock is exploring the potential of ASK1 inhibitors for treating various other conditions, including cardiac, immunological, and neurodegenerative diseases, which currently lack effective therapies.

Embolx, Inc. is a medical device company based in Sunnyvale, California, specializing in catheter-based systems for cancer therapy. Founded in 2013, the company develops innovative devices that enhance minimally invasive treatments, particularly through a technology known as Low Pressure Embolization (LPE). Their flagship product, the Sniper drug delivery balloon microcatheter, allows for precise tracking and controlled drug delivery, significantly improving tumor treatment while minimizing non-target flow and protecting surrounding tissues. Embolx's advanced microcatheters are designed not only for cancerous tumors but also for conditions such as benign prostatic hyperplasia and uterine fibroids, setting a new standard in embolic delivery and targeting effectiveness.

InvVax, Inc. is a vaccine development company based in Los Angeles, California, founded in 2012. The company focuses on creating innovative vaccines, with its primary product being a universal influenza vaccine aimed at preventing pandemics. Utilizing a proprietary platform, InvVax's technology analyzes influenza proteins to address virus mutations, thereby enhancing the effectiveness of vaccines. In addition to its work on influenza, InvVax is exploring vaccine candidates for other viral infections, including HIV, Hepatitis B, and Hepatitis C.

Embolx, Inc. is a medical device company based in Sunnyvale, California, specializing in catheter-based systems for cancer therapy. Founded in 2013, the company develops innovative devices that enhance minimally invasive treatments, particularly through a technology known as Low Pressure Embolization (LPE). Their flagship product, the Sniper drug delivery balloon microcatheter, allows for precise tracking and controlled drug delivery, significantly improving tumor treatment while minimizing non-target flow and protecting surrounding tissues. Embolx's advanced microcatheters are designed not only for cancerous tumors but also for conditions such as benign prostatic hyperplasia and uterine fibroids, setting a new standard in embolic delivery and targeting effectiveness.

Ask.Vet is an online platform that connects pet owners with licensed veterinarians, offering expert advice on a variety of topics related to animal care and well-being. Designed to serve the needs of the two hundred million households with pets worldwide, Ask.Vet allows users to pose questions that are directed to trained veterinarians who provide guidance, education, and referrals to local veterinary services for further diagnosis and treatment. The platform emphasizes a personalized experience, addressing issues ranging from general wellness and nutrition to specific health concerns. Additionally, veterinarians, clinics, and service providers can pay a referral fee to Ask.Vet for qualified leads, enhancing the platform's ecosystem for both pet owners and veterinary professionals.

Ask.Vet is an online platform that connects pet owners with licensed veterinarians, offering expert advice on a variety of topics related to animal care and well-being. Designed to serve the needs of the two hundred million households with pets worldwide, Ask.Vet allows users to pose questions that are directed to trained veterinarians who provide guidance, education, and referrals to local veterinary services for further diagnosis and treatment. The platform emphasizes a personalized experience, addressing issues ranging from general wellness and nutrition to specific health concerns. Additionally, veterinarians, clinics, and service providers can pay a referral fee to Ask.Vet for qualified leads, enhancing the platform's ecosystem for both pet owners and veterinary professionals.

Thrive Bioscience, Inc. is a life science company based in Beverly, Massachusetts, that specializes in automated non-microbial cell culture instruments aimed at enhancing research, drug discovery, drug development, and regenerative medicine. Established in 2014, the company offers a range of instruments and software that facilitate imaging, analytics, and automation for live cell biology. Its flagship product, CellAssist, allows researchers to image, analyze, and document various aspects of cell cultures in a centralized system, promoting consistent and reproducible results. By integrating microscopy, robotics, and fluidics, Thrive's technology captures extensive data on live cells and tissues, supporting advancements in artificial intelligence and machine learning. The company is also focused on developing software modules that enhance drug discovery workflows, thereby improving experimental assays and research insights for medical professionals engaged in cell and stem cell culture.

InvVax, Inc. is a vaccine development company based in Los Angeles, California, founded in 2012. The company focuses on creating innovative vaccines, with its primary product being a universal influenza vaccine aimed at preventing pandemics. Utilizing a proprietary platform, InvVax's technology analyzes influenza proteins to address virus mutations, thereby enhancing the effectiveness of vaccines. In addition to its work on influenza, InvVax is exploring vaccine candidates for other viral infections, including HIV, Hepatitis B, and Hepatitis C.

Retrotope Inc. is a pharmaceutical company focused on developing therapeutics for degenerative diseases, particularly those affecting mitochondrial health. Founded in 2006 and based in Los Altos, California, Retrotope specializes in addressing conditions such as Parkinson's disease, Alzheimer's disease, mitochondrial myopathies, and retinopathies. The company is known for its drug RT001, which targets infantile neuroaxonal dystrophy, and it employs a unique drug platform that utilizes isotope effects to mitigate oxidative stress and cellular damage. Through several discovery and development programs, Retrotope aims to create innovative solutions for a range of neurological disorders, including Friedreich's ataxia, while also contributing to the broader understanding of metabolic processes related to these conditions.

Ask.Vet is an online platform that connects pet owners with licensed veterinarians, offering expert advice on a variety of topics related to animal care and well-being. Designed to serve the needs of the two hundred million households with pets worldwide, Ask.Vet allows users to pose questions that are directed to trained veterinarians who provide guidance, education, and referrals to local veterinary services for further diagnosis and treatment. The platform emphasizes a personalized experience, addressing issues ranging from general wellness and nutrition to specific health concerns. Additionally, veterinarians, clinics, and service providers can pay a referral fee to Ask.Vet for qualified leads, enhancing the platform's ecosystem for both pet owners and veterinary professionals.

Zephyrus Biosciences, Inc. is a life science research tools company based in Berkeley, California, founded in 2013. The company specializes in the development and commercialization of innovative research tools that facilitate protein analysis at the single-cell level. Its flagship product, the scWestern System, allows for western blotting on individual cells, a significant advancement in the field of single-cell analysis. This system employs microfluidics technology to isolate single cells in micro-wells, lysing them and performing SDS-PAGE separation on each lysate. Researchers utilize Zephyrus's tools to explore critical areas such as cancer biology, stem cell research, neurology, and broader human disease studies, ultimately contributing to advancements in diagnostics and therapeutics. As of March 2016, Zephyrus operates as a subsidiary of Bio-Techne Corp.

Nanotech Biomachines specializes in the development of advanced sensor technology aimed at transforming therapeutic discovery and development processes. By utilizing modern electronic materials and straightforward membrane preparations, the company achieves high sensitivity and specificity in its measurements. Its innovative approach employs naive biology to enable real-time, mass-independent, cell-free, and label-free detection of interactions with integral membrane proteins (IMPs). This technology offers a direct electronic output and utilizes native IMPs within fluid membranes, providing essential tools for clients engaged in the discovery and development of 21st-century medicines.

Sandstone Diagnostics is a Bay Area biotech company developing instruments and consumables for point-of-care medical testing. Sandstone’s lead product, Trak, is a consumer semen analysis platform that provides a simple and accurate way to monitor sperm quality from the comfort of home. Trak is a tool for men to take charge of their fertility, boost their sperm quality, and improve their chances of conception. Sandstone was co-founded in 2012 by Ph.D. scientists developing medical technologies for national defense applications at Sandia National Laboratories.

Gemmus Pharma Inc. is a biotechnology company based in San Francisco, California, founded in 2007. The company focuses on developing therapeutics for the treatment of influenza and other infectious diseases. Its lead candidates include GP1001, a non-peptidic eicosanoid analog designed for serious influenza infections that may require hospitalization, and GP1681, which aims to alleviate influenza symptoms by reducing the exaggerated cytokine response induced by the virus. GP1001 can be used as a stand-alone treatment or in combination with antiviral drugs such as oseltamivir. Gemmus Pharma has received support from the National Institute of Allergy and Infectious Disease and has plans to file an investigational new drug application with the FDA to advance its influenza treatment initiatives.

Physcient, Inc. is a manufacturer of surgical instruments, specializing in the Differential Dissector, which is designed for blunt dissection. This device is utilized in various surgical fields, including plastic surgery and general surgery procedures such as thoracic, gastrointestinal, gynecological, urological, peripheral vascular, and orthopedic surgeries. Founded in 2007 and headquartered in Durham, North Carolina, Physcient focuses on developing modern technology for hand-held surgical instruments that facilitate quicker recovery without altering existing surgical techniques. The company's founders bring over 75 years of combined experience in advancing technologies within the life and health sciences.

Carmenta Bioscience, Inc. is a medical technology company focused on enhancing maternal and fetal health through the development of a serum-based diagnostic test for preeclampsia. Founded in 2012 as a spin-out from Stanford University School of Medicine and based in Palo Alto, California, the company utilizes a systems biology approach to improve the accuracy of diagnosing and predicting preeclampsia. As of 2015, Carmenta operates as a subsidiary of Progenity, Inc.

NuMedii, Inc. is a biotechnology company focused on discovering and developing drug candidates by leveraging life sciences big data technology. Founded in 2008 and headquartered in San Mateo, California, NuMedii utilizes an extensive array of biological, pharmacological, and clinical data to identify new therapeutic options and indications for existing drugs. The company aims to de-risk drug candidates by analyzing complex biological networks related to diseases, thereby addressing unmet medical needs. NuMedii collaborates with pharmaceutical companies for the clinical development and commercialization of its drug candidates, supported by strategic alliances with partners such as Aptalis Pharma and Three Lakes Partners, LLC.

NanoStim is an early-stage medical device company focused on developing a miniaturized, leadless cardiac pacemaker aimed at reducing complications associated with traditional pacemakers, which affect over 100,000 individuals annually. The company has assembled a highly skilled team of medical device engineers to advance this innovative technology, which is designed for direct implantation in a cardiac chamber without the need for leads. By offering a leadless pacing solution, NanoStim seeks to improve patient outcomes and enhance the safety and effectiveness of cardiac interventions.

nVision Medical Corporation is a medical device company focused on addressing female health issues, specifically infertility caused by fallopian tube dysfunction and ovarian cancer detection. Founded in 2009 and based in Saratoga, California, nVision Medical develops innovative devices that allow clinicians to assess the health of previously inaccessible areas of the female reproductive tract. The company aims to fill significant gaps in women's health innovation by creating technologies that enhance diagnosis and treatment options. As of 2018, nVision Medical operates as a subsidiary of Boston Scientific Corporation, further leveraging resources to advance its mission in the healthcare sector.

Gemmus Pharma Inc. is a biotechnology company based in San Francisco, California, founded in 2007. The company focuses on developing therapeutics for the treatment of influenza and other infectious diseases. Its lead candidates include GP1001, a non-peptidic eicosanoid analog designed for serious influenza infections that may require hospitalization, and GP1681, which aims to alleviate influenza symptoms by reducing the exaggerated cytokine response induced by the virus. GP1001 can be used as a stand-alone treatment or in combination with antiviral drugs such as oseltamivir. Gemmus Pharma has received support from the National Institute of Allergy and Infectious Disease and has plans to file an investigational new drug application with the FDA to advance its influenza treatment initiatives.

Niveus Medical, Inc. is a company that specializes in muscle stimulation systems aimed at preventing muscle atrophy, particularly in patients who are sedated or on bed rest. Founded in 2008 and based in Redwood City, California, Niveus Medical develops technologies that stimulate the quadriceps, facilitating the maintenance or increase of knee joint range of motion. Their systems are designed to re-educate muscles, alleviate spasms, and enhance local blood circulation. By providing effective stimulation, Niveus Medical's products enable faster treatment initiation, ultimately improving the chances of successful patient recovery in intensive care settings. The company operates under the brand IntelliSTIM.

MoMelan Technologies, Inc. is a company based in Cambridge, Massachusetts, specializing in the development of a device designed to treat skin disorders through the expansion of skin grafts. Founded in 2009, the company has created a tabletop device that can significantly increase the surface area of a small amount of harvested skin—up to approximately 100 times its original size. This innovative technology enables the grafting of expanded skin onto various areas affected by scars or other skin damage, thereby improving treatment options for patients. MoMelan operates as a subsidiary of Acelity L.P. Inc.

OncoHealth is a company that specializes in creating screening devices aimed at the detection and diagnosis of cancer. The primary focus of its devices is the development of protein bio-markers, which are essential for the screening and diagnostic processes related to cervical cancer and other cancers associated with human papillomavirus (HPV). By advancing these technologies, OncoHealth enables medical professionals to effectively monitor, diagnose, and treat cancer, thereby contributing to improved patient outcomes in oncology.

OncoHealth is a company that specializes in creating screening devices aimed at the detection and diagnosis of cancer. The primary focus of its devices is the development of protein bio-markers, which are essential for the screening and diagnostic processes related to cervical cancer and other cancers associated with human papillomavirus (HPV). By advancing these technologies, OncoHealth enables medical professionals to effectively monitor, diagnose, and treat cancer, thereby contributing to improved patient outcomes in oncology.

Allylix, Inc. is an early-stage biotechnology company based in San Diego, California, with research and development laboratories in Lexington, Kentucky. Founded in 2002, the company specializes in developing terpene products and their derivatives for various markets, including flavor and fragrance, food ingredients, pharmaceuticals, agriculture, and biofuels. Notable among its offerings is nootkatone, a grapefruit flavor used in beverages such as fruit juices and citrus-flavored sodas. Additionally, Allylix works on sesquiterpenes that contribute to the aroma chemical segment of the flavor and fragrance industry, as well as production platforms for the pharmaceutical and nutraceutical sectors.

Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.

Vaxart, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, specializing in the discovery and development of oral recombinant protein vaccines using its proprietary vaccine platform. The company is focused on creating oral vaccines that can generate broad and durable immune responses against various infectious diseases. Its product pipeline includes an oral tablet vaccine for norovirus, which has completed Phase I clinical trials, a seasonal influenza vaccine currently in Phase II trials, and vaccines targeting respiratory syncytial virus and coronavirus. Additionally, Vaxart is developing therapeutic vaccines for human papillomavirus-related conditions. The company aims to improve vaccination rates by offering a convenient, room temperature-stable tablet format, which is easier to distribute and administer compared to traditional injectable vaccines. Vaxart also has a research collaboration with Janssen Vaccines & Prevention B.V. to explore its oral vaccine platform for a universal influenza vaccine program.

Velomedix, Inc. is a therapeutic hypothermia company based in Menlo Park, California. The company specializes in technologies designed to protect the body’s organs during ischemic or inflammatory insults. Velomedix's innovative approach aims to provide an effective solution for preserving organ function in critical medical situations.

Verdezyne is a private company focused on synthetic biology, utilizing its expertise and advanced computational algorithms to design and synthesize diverse gene libraries for engineering proteins, metabolic pathways, and microorganisms. By optimizing commercial fermentation processes, Verdezyne produces renewable chemical alternatives to petrochemicals. The company’s innovative platform combines synthetic biology with established manufacturing technologies to create a wide range of building blocks, offering sustainable and cost-effective solutions for everyday chemicals and additives. This approach aims to reduce reliance on oil and transform traditional chemical production methods.

Breathe Technologies, Inc. is a medical technology company based in Irvine, California, that specializes in developing and manufacturing innovative respiratory therapies for treating respiratory insufficiency diseases. Founded in 2005, the company focuses on creating non-invasive open ventilation systems aimed at helping patients with conditions such as interstitial lung diseases, neuromuscular disorders, and those undergoing lung transplants. Their lightweight, volume-control mechanical ventilators are designed to enhance patient mobility and are suitable for use in various healthcare settings, including general medical units, intensive care, and pulmonary rehabilitation. As a subsidiary of Hill-Rom, Breathe Technologies is committed to providing reliable and accessible solutions that optimize breathing and improve the quality of life for patients both in hospital and home environments.

Satoris is a company focused on the development and commercialization of neurodiagnostic tests aimed at identifying neurological diseases such as Alzheimer's, Parkinson's, Multiple Sclerosis, and Diabetic Neuropathy. The company is dedicated to creating tests that provide early, accurate, and clinically relevant diagnoses, which can lead to improved patient care and reduced healthcare costs. By prioritizing convenience and affordability, Satoris aims to enhance access to essential diagnostic services for patients facing these neurological conditions.

Allylix, Inc. is an early-stage biotechnology company based in San Diego, California, with research and development laboratories in Lexington, Kentucky. Founded in 2002, the company specializes in developing terpene products and their derivatives for various markets, including flavor and fragrance, food ingredients, pharmaceuticals, agriculture, and biofuels. Notable among its offerings is nootkatone, a grapefruit flavor used in beverages such as fruit juices and citrus-flavored sodas. Additionally, Allylix works on sesquiterpenes that contribute to the aroma chemical segment of the flavor and fragrance industry, as well as production platforms for the pharmaceutical and nutraceutical sectors.

Vaxart, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, specializing in the discovery and development of oral recombinant protein vaccines using its proprietary vaccine platform. The company is focused on creating oral vaccines that can generate broad and durable immune responses against various infectious diseases. Its product pipeline includes an oral tablet vaccine for norovirus, which has completed Phase I clinical trials, a seasonal influenza vaccine currently in Phase II trials, and vaccines targeting respiratory syncytial virus and coronavirus. Additionally, Vaxart is developing therapeutic vaccines for human papillomavirus-related conditions. The company aims to improve vaccination rates by offering a convenient, room temperature-stable tablet format, which is easier to distribute and administer compared to traditional injectable vaccines. Vaxart also has a research collaboration with Janssen Vaccines & Prevention B.V. to explore its oral vaccine platform for a universal influenza vaccine program.

Fluxion Biosciences develops analytical instruments for functional cellular analyses, targeting applications in life sciences, drug discovery, and diagnostics. The company offers a range of products, including the IsoFlux Liquid Biopsy System, which enriches rare cell populations such as circulating tumor cells, and various enrichment and downstream analysis kits. Additionally, Fluxion provides BioFlux systems for live cell analysis under shear flow, catering to fields like immunology and cancer research, as well as IonFlux systems for automated patch clamping. Founded in 2005 and based in Alameda, California, Fluxion also offers analytical services for circulating tumor cell and liquid biopsy applications, serving biotechnology and pharmaceutical companies, academic institutions, and government research organizations through a global network of distributors.

Verdezyne is a private company focused on synthetic biology, utilizing its expertise and advanced computational algorithms to design and synthesize diverse gene libraries for engineering proteins, metabolic pathways, and microorganisms. By optimizing commercial fermentation processes, Verdezyne produces renewable chemical alternatives to petrochemicals. The company’s innovative platform combines synthetic biology with established manufacturing technologies to create a wide range of building blocks, offering sustainable and cost-effective solutions for everyday chemicals and additives. This approach aims to reduce reliance on oil and transform traditional chemical production methods.

VasoNova, Inc. is a medical device company based in Sunnyvale, California, specializing in the development and marketing of vascular navigation systems for healthcare providers. The company has created a self-guided PICC catheter and offers the VasoNova Vascular Positioning System, an algorithm-based system designed to assist clinicians in the optimal placement of vascular access devices. Through its innovative technologies, VasoNova aims to enhance the efficiency and effectiveness of vascular access procedures in medical settings.

Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases, particularly within the central nervous system. The company is headquartered in Emeryville, California, and was established in 2006. Its lead product candidate, Fintepla, is a low-dose fenfluramine currently undergoing Phase III clinical trials for the treatment of seizures related to Dravet syndrome and Lennox-Gastaut syndrome. Additionally, it is being investigated in Phase II trials for other rare epileptic conditions. Zogenix is also developing MT1621, a therapy aimed at treating inherited mitochondrial DNA depletion disorders. Furthermore, the company collaborates with Tevard Biosciences to explore gene therapies for Dravet syndrome and similar genetic epilepsies. By focusing on therapies that address significant unmet medical needs, Zogenix aims to enhance the quality of life for patients and their families.

Verdezyne is a private company focused on synthetic biology, utilizing its expertise and advanced computational algorithms to design and synthesize diverse gene libraries for engineering proteins, metabolic pathways, and microorganisms. By optimizing commercial fermentation processes, Verdezyne produces renewable chemical alternatives to petrochemicals. The company’s innovative platform combines synthetic biology with established manufacturing technologies to create a wide range of building blocks, offering sustainable and cost-effective solutions for everyday chemicals and additives. This approach aims to reduce reliance on oil and transform traditional chemical production methods.

Pegasus Biologics, Inc. engages in manufacturing, developing, and marketing bioimplants for soft tissue repair and wound care for diabetic ulcers. Its products include OrthADAPT Bioimplant, which is an organized tissue scaffold that used for the repair and reinforcement of soft tissues, such as tendons and ligaments; and Unite Biomatrix, which is an enzyme resistant collagen scaffold that allows for suture retention and intrinsic strength. The company serves orthopedics, sports medicine, neurosurgical, and spine applications. Pegasus Biologics, Inc. was founded in 2003 and is based in Irvine, California. As of July 17, 2009, Pegasus Biologics, Inc. operates as a subsidiary of Synovis Life Technologies Inc.